Metabolomics signature as a survival predictor in patients with resectable colorectal liver metastasis

Carmen González-Olmedo; Francisco José García-Verdejo; Antonio Reguera-Teba; Carmen Rosa-Garrido; José Antonio López-López; Leticia Díaz-Beltrán; Patricia Mena García; Natalia Luque-Caro; Fernando Gálvez-Montosa; Ana Laura Ortega-Granados; María Ruiz-Sanjuan; Antonio Cózar-Ibáñez; Juan Sainz; Juan Antonio Marchal; José Camacho; José Pérez del Palacio; Rosario Fernández-Godino; Caridad Díaz; Pedro Sánchez-Rovira

doi:10.1002/ctm2.1541

Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (1) : e1541 DOI: 10.1002/ctm2.1541

LETTER TO THE JOURNAL

Metabolomics signature as a survival predictor in patients with resectable colorectal liver metastasis

Author information +

¹. Medical Oncology Unit, University Hospital of Jaén, Jaén, Spain

². Fundación Pública Andaluza para la Investigación Biosanitaria de Andalucía Oriental Alejandro Otero, University Hospital of Jaén, Jaén, Spain

³. Department of Biomedicine, Translational Research and Personalised Medicine, University of Granada, Granada, Spain

⁴. Department of General Surgery, University Hospital of Jaén, Jaén, Andalucia, Spain

⁵. Department of Medicine, Faculty of Health Sciences, University of Jaén, Jaén, Spain

⁶. Fundación MEDINA, Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía, Armilla, Granada, Spain

⁷. Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer, University of Granada, Andalusian Regional Government, PTS, Granada, Spain

⁸. Instituto de Investigación Biosanataria IBs.Granada, Granada, Spain

⁹. Consortium for Biomedical Research in Epidemiology and Public Health, Barcelona, Spain

¹⁰. Department of Biochemistry and Molecular Biology I, University of Granada, Granada, Spain

¹¹. Biopathology and Regenerative Medicine Institute, Centre for Biomedical Research, University of Granada, Granada, Spain

¹². Department of Human Anatomy and Embryology, Faculty of Medicine, University of Granada, Granada, Spain

¹³. Excellence Research Unit “Modeling Nature” (MNat), University of Granada, Granada, Spain

¹⁴. Department of Signal Theory, Networking and Communications, University of Granada, Granada, Spain

caridad.diaz@medinaandalucia.es

Show less

History +

PDF

Cite this article

Download citation ▾

Carmen González-Olmedo, Francisco José García-Verdejo, Antonio Reguera-Teba, Carmen Rosa-Garrido, José Antonio López-López, Leticia Díaz-Beltrán, Patricia Mena García, Natalia Luque-Caro, Fernando Gálvez-Montosa, Ana Laura Ortega-Granados, María Ruiz-Sanjuan, Antonio Cózar-Ibáñez, Juan Sainz, Juan Antonio Marchal, José Camacho, José Pérez del Palacio, Rosario Fernández-Godino, Caridad Díaz, Pedro Sánchez-Rovira. Metabolomics signature as a survival predictor in patients with resectable colorectal liver metastasis. Clinical and Translational Medicine, 2024, 14(1): e1541 DOI:10.1002/ctm2.1541

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.

[2]	Sociedad Española de Oncología Médica (SEOM). Red Española de Registros del Cáncer (REDECAN). Las Cifras Del Cáncer En España; 2022. Accessed April 28, 2023CIFRAS DEL CANCER EN ESPAÑA 2022.pdf

[3]	Kow AWC. Hepatic metastasis from colorectal cancer. J Gastrointest Oncol. 2019;10(6):1274-1298.

[4]	Gold A, Choueiry F, Jin N, et al. The application of metabolomics in recent colorectal cancer studies: a state-of-the-art review. Cancers (Basel). 2022;14(3):725.

[5]	Jonas JP, Hackl H, Pereyra D, et al. Circulating metabolites as a concept beyond tumor biology determining disease recurrence after resection of colorectal liver metastasis. HPB (Oxford). 2022;24(1):116-129.

[6]	Zhang J, Zou S, Fang L. Metabolic reprogramming in colorectal cancer: regulatory networks and therapy. Cell Biosci. 2023;13(1):1-21.

[7]	Law SH, Chan ML, Marathe GK, et al. An updated review of lysophosphatidylcholine metabolism in human diseases. Int J Mol Sci. 2019;20(5):1149.

[8]	Li H, Zhang C, Zhang H, et al. Xanthine oxidoreductase promotes the progression of colitis-associated colorectal cancer by causing DNA damage and mediating macrophage M1 polarization. Eur J Pharmacol. 2021;906:174270.

[9]	Ridlon JM, Wolf PG, Gaskins HR. Taurocholic acid metabolism by gut microbes and colon cancer. Gut Microbes. 2016;7:201-215.

[10]	De Almeida CV, Rodrigues de Camargo M, Russo E, et al. Role of diet and gut microbiota on colorectal cancer immunomodulation. World J Gastroenterol. 2019;25:151-162.

RIGHTS & PERMISSIONS

2024 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.